Keyphrases
Transplantation
100%
Highly Sensitized
100%
Left Ventricular Assist Device
100%
Panel-reactive Antibody
100%
Alemtuzumab
100%
Pheresis
100%
Plasmapheresis
30%
Heart Transplantation
30%
Acute Rejection
20%
T Cells
10%
B Lymphocytes
10%
Clinical Course
10%
Consecutive Patients
10%
Antibody Level
10%
Lung Transplantation
10%
Highly Sensitized Patients
10%
International Society
10%
Positive Crossmatch
10%
Heart Transplant
10%
Basiliximab
10%
Antibody-mediated Rejection
10%
Humoral Rejection
10%
Cellular Rejection
10%
Surveillance Strategy
10%
Demand Adjustment
10%
Transplant Waiting List
10%
Lymphocytotoxic Crossmatch
10%
Mid-term Survival
10%
ABO Incompatibility
10%
Medicine and Dentistry
Alemtuzumab
100%
Left Ventricular Assist Device
100%
Panel Reactive Antibody
100%
Plasmapheresis
75%
Heart Transplantation
75%
Acute Graft Rejection
50%
T Lymphocyte
25%
Immunosuppressive Drug
25%
Transplantation
25%
Disease Course
25%
Lung Transplantation
25%
B Lymphocyte
25%
Heart Graft
25%
Antibody Mediated Rejection
25%
Humoral Rejection
25%
Cellular Rejection
25%
Basiliximab
25%
Pharmacology, Toxicology and Pharmaceutical Science
Panel Reactive Antibody
100%
Alemtuzumab
100%
Acute Graft Rejection
50%
Disease Course
25%
Immunosuppressive Agent
25%
Basiliximab
25%